World's First DHX33-Targeted Anti-Cancer Drug KY2 Receives CDE Clearance for Clinical Trials

2025-06-23

Shenzhen KeYe Life Technology Co., Ltd. was Awarded ISO 13485 Certification

2025-05-08

KeYe Life ’s Investigational Drug KY2 is Accepted by China’s Center for Drug Evaluation (CDE)

2025-04-15

KeYe Life's KY1 Enters Phase I Clinical Trial at Ruijin

2025-03-20

Keye Life's KY2 Oral Small-Molecule Drug Receives FDA Investigational New Drug (IND) Implicit Approval.

2025-02-22

KY1 completes first patient dosing in Phase I clinical trial

2024-10-25

Russian Academy of Engineering Foreign Academician Dr. Zhang Dan was Invited to Visit and Guide Clinical Trials

2024-10-25

KeYe Biotech Successfully Holds KY1 Product Clinical Trial Kickoff Meeting

2024-10-25

KeYe Biotech Receives "High Growth Enterprise" Designation

2024-10-25

KeYe Life's KY1 molecule has received orphan drug designation (ODD) from the FDA for gastric cancer

2024-10-22